Abbott Laboratories Limited

Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK
Telephone: +44 (0)1628 773 355
Fax: +44 (0)1628 644 185
WWW: http://www.abbottuk.com
Medical Information e-mail: ukmedinfo@abbott.com
Out of Hours Telephone: +44 (0)1628 774 920

Patient Information Leaflet last updated on the eMC: 22/12/2011
PIL Humira 40 mg solution for injection in pre-filled syringe

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 09/06/2011 and displayed until 22/12/2011
Reasons for adding or updating:
  • Change to date of revision
  • Introduction of new pack/pack size
Updated on 03/03/2011 and displayed until 09/06/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 19/10/2010 and displayed until 03/03/2011
Reasons for adding or updating:
  • Change to side-effects
  • Change to information about driving or using machinery
Updated on 05/07/2010 and displayed until 19/10/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 21/05/2010 and displayed until 05/07/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 10/08/2009 and displayed until 21/05/2010
Reasons for adding or updating:
  • Change to side-effects
Updated on 16/03/2009 and displayed until 10/08/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 20/10/2008 and displayed until 16/03/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to information about driving or using machinery
  • Change to dosage and administration
Updated on 16/01/2008 and displayed until 20/10/2008
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 18/07/2007 and displayed until 16/01/2008
Reasons for adding or updating:
  • Changes to therapeutic indications
  • Change to side-effects
Updated on 13/06/2006 and displayed until 18/07/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 10/02/2006 and displayed until 13/06/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 10/02/2006 and displayed until 10/02/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 10/11/2005 and displayed until 10/02/2006
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   adalimumab